UPC_CFI_165/2024

PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF

Einstweilige MaßnahmenEinstweilige MaßnahmenDusseldorf LDProvisional measuresCase Closed

Übersicht Entscheidungen Begründung Zitate Dokumente Zeitverlauf

Parteien

Kläger

Novartis AG
Genentech, Inc.

Vertreter: Frank-Erich Hufnagel (Freshfields Bruckhaus Deringer); Kilian Seidel (Freshfields Bruckhaus Deringer); Cameron Marshall (Carpmaels & Ransford); Joanna Rowley (Carpmaels & Ransford)

Beklagte

Celltrion Healthcare Hungary Kft.
Celltrion Healthcare Deutschland GmbH
Celltrion Healthcare Belgium SPRL
Celltrion Healthcare France SAS
Celltrion Healthcare Finland Oy
Celltrion Healthcare Italy S.R.L.
Celltrion Healthcare Netherlands B.V.

Vertreter: (not specified) ((Celltrion representatives))

Richter

Berenice Thom
Berenice Thom
Alima Zana
John Petersen

Patente

EP3805248
EP 3 805 248 B1

CPC-Codes: B01D2311/04, A61K39/39591, B01D2311/16, B01D61/146, C07K16/065, C07K2317/21, C07K16/4291, C07K1/34, B01D61/16

Sektor: Organic Chemistry

Ausgang

PI abgelehnt

Eingereicht: 9. Apr. 2024

Erste Entscheidung: —

Sprache: English

Order of Düsseldorf Local Division rejecting Novartis/Genentech's application for provisional measures against Celltrion Healthcare entities regarding EP 3 805 248 B1 (biosimilar product Epysqli). The court found the requirements for provisional measures were not met and ordered Novartis/Genentech to pay interim costs of EUR 138,562.80. The court set out important headnotes on: the interpretation of Art. 25 and 62 UPCA as autonomous uniform law; the concept of imminent infringement; group company liability; inapplicability of R. 295 RoP to provisional measures applications; and parties' obligation to present focused technical arguments.

Im UPC-Register öffnen